Core Viewpoint - The article discusses the blood purification device industry, highlighting the increasing prevalence of End-Stage Renal Disease (ESRD) and the growth potential of blood purification technologies in response to this global health challenge [18][21]. Market Overview - The global ESRD patient population is projected to grow from 91.33 million in 2019 to 148.51 million by 2030, with a CAGR of 4.2% [18][19]. - In China, the ESRD patient population is expected to increase from 3.025 million in 2019 to 6.132 million by 2030, with a CAGR of 5.8% [20][18]. Treatment Methods - Blood purification is the most widely used treatment for ESRD, offering higher survival rates compared to kidney transplantation and conservative treatment [21]. - The number of patients receiving blood purification treatment in China rose from 736,000 in 2019 to 1.069 million in 2023, with a CAGR of 9.8%, and is expected to reach 3.791 million by 2030, with a CAGR of 19.8% [21][23]. Blood Purification Technologies - The main blood purification methods include hemodialysis, peritoneal dialysis, blood perfusion, and blood filtration, with hemodialysis being the most mature and widely applied [29]. - Hemodialysis effectively removes harmful substances and excess fluid from the blood, making it suitable for patients at various disease stages [29]. Market Size and Growth - The Chinese blood dialysis device market is projected to grow from CNY 11.63 billion in 2019 to CNY 51.52 billion by 2030, with a CAGR of 19.9% from 2023 to 2030 [30][28]. - The market share of blood dialysis devices in China is expected to see significant growth, with specific segments like blood dialysis machines and consumables also experiencing robust growth rates [30]. Competitive Landscape - Domestic companies are rapidly catching up with international competitors in the blood purification consumables sector, achieving nearly 50% market share in dialysis filters [31]. - The competitive landscape for blood dialysis machines is evolving, with domestic manufacturers improving their technology and performance to match imported products [37][33]. Policy and Market Dynamics - The article notes that the Chinese government has been implementing centralized procurement policies, leading to significant price reductions and accelerating the domestic replacement process in the blood purification market [36][35].

www.hczq.com 证券研究报告 | 医药生物 | 2025年11月29日 华创医药投资观点&研究专题周周谈 · 第152期 血液净化器械行业专题 本周专题联系人：李婵娟 陈俊威 华创医药团队： | 首席分析师 郑辰 | | | --- | --- | | 联席首席分析师 | 刘浩 | | 医疗器械组组长 | 李婵娟 | | 中药和流通组组长 | 高初蕾 | | 分析师 | 王宏雨 | | 分析师 | 朱珂琛 | | 分析师 | 陈俊威 | | 分析师 张良龙 | | | 执业编号：S0360520110002 | 邮箱：zhengchen@hcyjs.com | | --- | --- | | 执业编号：S0360520120002 | 邮箱：liuhao@hcyjs.com | | 执业编号：S0360520110004 | 邮箱：lichanjuan@hcyjs.com | | 执业编号：S0360524070002 | 邮箱：gaochulei@hcyjs.com | | 执业编号：S0360523080006 | 邮箱：wanghongyu@hcyjs.com | | 执业编号：S036052 ...

证券日报网讯 11月25日晚间，宝莱特发布公告称，根据相关规定，"宝莱转债"将于公司2025年前三季 度权益分派股权登记日后的第一个交易日，即2025年11月26日（除权除息日）起恢复转股。敬请公司可 转换公司债券持有人留意。 （文章来源：证券日报） ...

| 股票简称：宝莱特 | 股票代码：300246 | | --- | --- | | 债券简称：宝莱转债 | 债券代码：123065 | 财通证券股份有限公司 关于广东宝莱特医用科技股份有限公司 向不特定对象发行可转换公司债券 2025 年度第 1 次临时受托管理事务报告 债券受托管理人 二零二五年十一月 （四）债券期限：6 年。 （五）债券利率：第一年为 0.4%、第二年为 0.7%、第三年为 1.0%、第四年 为 1.8%、第五年为 2.5%、第六年为 3.5%。 声 明 本报告依据《公司债券发行与交易管理办法》《公司债券受托管理人执业行 为准则》《广东宝莱特医用科技股份有限公司与财通证券股份有限公司关于广东 宝莱特医用科技股份有限公司 2020 年向不特定对象发行可转换公司债券之受托 管理协议》（以下简称 "《债券受托管理协议》"）《广东宝莱特医用科技股 份有限公司创业板向不特定对象发行可转换公司债券募集说明书》（以下简称 "《募集说明书》"）等公开信息披露文件以及广东宝莱特医用科技股份有限公 司（以下简称"公司"）出具的相关公告、说明文件等，由债券受托管理人财通 证券股份有限公司（以下简称"财通证券" ...

证券代码：300246 证券简称：宝莱特 公告编号：2025-085 债券代码：123065 债券简称：宝莱转债 根据相关规定，"宝莱转债"将于公司2025年前三季度权益分派股权登记日 后的第一个交易日，即2025年11月26日（除权除息日）起恢复转股。敬请公司可 转换公司债券持有人留意。 特此公告。 广东宝莱特医用科技股份有限公司 1、债券代码：123065 2、债券简称：宝莱转债 3、可转换公司债券转股的起止日期：2021 年 3 月 11 日至 2026 年 9 月 3 日 4、暂停转股时间：2025 年 11 月 18 日至 2025 年 11 月 25 日 广东宝莱特医用科技股份有限公司 关于宝莱转债恢复转股的提示性公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 特别提示： 5、恢复转股时间：2025 年 11 月 26 日 广东宝莱特医用科技股份有限公司（以下简称"宝莱特"或"公司"）因实 施2025年前三季度权益分派，根据《广东宝莱特医用科技股份有限公司创业板向 不特定对象发行可转换公司债券募集说明书》及《深圳证券交易所创业板上市公 司自律监管 ...

分组1 - 莱绅通灵 announced a cash dividend of 0.10 yuan per share (tax included), with the record date on November 24, 2025, and the ex-dividend date on November 25, 2025 [1] - 卫信康 declared a cash dividend of 0.147 yuan per share (tax included), with the record date on November 25, 2025, and the ex-dividend date on November 26, 2025 [1] - 宏辉果蔬 issued a cash dividend of 0.005 yuan per share (tax included), with the record date on November 24, 2025, and the ex-dividend date on November 25, 2025 [1] 分组2 - 杭叉集团 reported a cash dividend of 0.2 yuan per share (tax included), with the record date on November 25, 2025, and the ex-dividend date on November 26, 2025 [2] - 新坐标 announced a cash dividend of 0.25 yuan per share (tax included), with the record date on November 25, 2025, and the ex-dividend date on November 26, 2025 [2] - 厦门象屿 declared a cash dividend of 0.1 yuan per share (tax included), with the record date on November 24, 2025, and the ex-dividend date on November 25, 2025 [2] 分组3 - 鼎泰高科 announced a cash dividend of 4.0 yuan for every 10 shares (tax included), with the record date on November 24, 2025, and the ex-dividend date on November 25, 2025 [3] - 宝莱特 declared a cash dividend of 0.494386 yuan for every 10 shares (tax included), with the record date on November 25, 2025, and the ex-dividend date on November 26, 2025 [3] - 华明装备 issued a cash dividend of 0.1999450 yuan per share (tax included), with the record date on November 24, 2025, and the ex-dividend date on November 25, 2025 [3] 分组4 - 金岭矿业 announced a cash dividend of 0.50 yuan for every 10 shares (tax included), with the record date on November 26, 2025, and the ex-dividend date on November 27, 2025 [4]

Core Points - The company Baolite announced a cash dividend distribution plan for the first three quarters of 2025, proposing a payment of 0.500000 RMB per 10 shares to all shareholders [2] - The total number of shares used as the basis for the distribution is 261,607,088 shares, excluding 2,970,600 shares that have been repurchased [2] - The record date for the dividend is set for November 25, 2025, and the ex-dividend date is November 26, 2025 [2]

证券代码：300246 证券简称：宝莱特 公告编号：2025-083 债券代码：123065 债券简称：宝莱转债 广东宝莱特医用科技股份有限公司 2025 年前三季度权益分派实施公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 特别提示： 1．根据《中华人民共和国公司法》《深圳证券交易所上市公司自律监管指 引第 9 号——回购股份》等相关规定，回购专用账户中持有的本公司股份不享 有参与利润分配的权利。因此，公司 2025 年前三季度权益分派以公司实施 2025 年前三季度利润分配方案时股权登记日总股本 264,577,688 股剔除已回购股份 2,970,600 股后的 261,607,088 股为基数。 2．公司本次年度权益分派按照"分配比例不变"（即向全体股东每 10 股 派发现金红利人民币 0.50 元（含税），不送红股，不以公积金转增股本）的原 则执行，合计派发现金红利 13,080,354.40 元人民币（含税）。 3．因回购股份不参与分红，本次权益分派实施后，根据股票市值不变原则， 实施权益分派前后公司总股本保持不变，现金分红总额分摊到每一股的比例 ...

Core Viewpoint - Baolite (300246.SZ) announced its equity distribution plan for the first three quarters of 2025, indicating a cash dividend of 0.05 RMB per share for all shareholders, with specific amounts for different categories of investors [1] Group 1 - The equity distribution plan is based on a total share capital of 262 million shares, excluding 2.9706 million repurchased shares [1] - The cash dividend is 0.05 RMB per share (before tax), with a net amount of 0.045 RMB per share for foreign institutions and certain individual investors [1] - The record date for the dividend is set for November 25, 2025, and the ex-dividend date is November 26, 2025 [1]

Group 1 - The company has announced a cash dividend distribution plan for the first three quarters of 2025, which has been approved by the shareholders' meeting [1] - The dividend will be distributed at a rate of 0.5 yuan per 10 shares (including tax), totaling 13.08 million yuan, based on a total share capital of 262 million shares after excluding 2.9706 million repurchased shares [1] - The record date for the dividend is set for November 25, and the ex-dividend date is November 26 [1] Group 2 - The conversion price for the "Baolai Convertible Bonds" will be adjusted from 24.02 yuan per share to 23.97 yuan per share, effective on November 26 [1]